Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Manal F. Abdelmalek"'
Autor:
Manal F. Abdelmalek, Jeongeun Hyun, Steven R. Patierno, Rebecca Caffrey, Cynthia A. Moylan, Muthana Al Abo, Anna Mae Diehl, Xiyou Zhou, Seh-Hoon Oh, Arun J. Sanyal, Kun Xiang, Rajesh Kumar Dutta, Raquel Maeso-Díaz, Jennifer A. Freedman
Publikováno v:
J Hepatol
Background & Aims Non-alcoholic fatty liver disease (NAFLD), the hepatic correlate of the metabolic syndrome, is a major risk factor for hepatobiliary cancer (HBC). Although chronic inflammation is thought to be the root cause of all these diseases,
Autor:
Sven Francque, Manal F. Abdelmalek, Veronica Miller, Claudia Filozof, Elmer Schabel, Katherine Barradas, Mazen Noureddin, Mark Berner-Hansen, Jörn M. Schattenberg, Stephanie O Omokaro, Oliver Glass
Publikováno v:
Journal of hepatology
Lifestyle modification is the foundation of treatment recommendations for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The design of clinical trials in NASH may be impeded by the lack of a systematic approach to
Autor:
Guadalupe Garcia-Tsao, Jaime Bosch, Zeid Kayali, Stephen A. Harrison, Manal F. Abdelmalek, Eric Lawitz, Sanjaya K. Satapathy, Marwan Ghabril, Mitchell L. Shiffman, Ziad H. Younes, Paul J. Thuluvath, Annalisa Berzigotti, Agustin Albillos, James M. Robinson, David T. Hagerty, Jean L. Chan, Arun J. Sanyal, M. Abdelmalek, K. Bhamidimarri, B. Borg, S. Caldwell, J. Fenkel, B. Freilich, M. Fuchs, M. Ghabril, R. Ghalib, S. Gonzalez, S. Gordon, B. Hameed, S. Harrison, Z. Kayali, N. Kemmer, K. Korenblat, M. Lai, C. Landis, E. Lawitz, W. Lee, S. Lidofsky, E. Mena, M. Noureddin, A. Paredes, N. Pyrsopoulos, R. Reddy, M. Rinella, D. Rockey, M. Rodriguez, M. Ryan, S. Sarkar, S. Satapathy, A. Scanga, M. Shiffman, M. Siddiqui, D. Simonetto, W. Syn, P. Thuluvath, R. Vemulapalli, J. Vierling, Z. Younes, A. Albillos, J. Arenas Ruiz-Tapiador, S. Augustin, J. Calleja, J. Crespo Garcia, L. Garcia Buey, J.C. Garcia-Pagan, C. Villanueva, C. Bureau, N. Carbonell, V. Leroy, P.-E. Rautou, H. Heinzow, I. Schiefke, A. Zipprich, A. Berzigotti, B. Muellhaupt
Publikováno v:
Garcia-Tsao, Guadalupe; Bosch, Jaime; Kayali, Zeid; Harrison, Stephen A; Abdelmalek, Manal F; Lawitz, Eric; Satapathy, Sanjaya K; Ghabril, Marwan; Shiffman, Mitchell L; Younes, Ziad H; Thuluvath, Paul J; Berzigotti, Annalisa; Albillos, Agustin; Robinson, James M; Hagerty, David T; Chan, Jean L; Sanyal, Arun J (2020). Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension. Journal of hepatology, 72(5), pp. 885-895. Elsevier 10.1016/j.jhep.2019.12.010
Background & Aims Emricasan, an oral pan-caspase inhibitor, decreased portal pressure in experimental cirrhosis and in an open-label study in patients with cirrhosis and severe portal hypertension, defined as a hepatic venous pressure gradient (HVPG)
Autor:
Elizabeth K. Fletcher, Athan Kuliopulos, Nga Nguyen, Srijoy Guha, Andrew Shearer, Daniel H. Cox, James D. Baleja, Ying Wang, Manal F. Abdelmalek, Lidija Covic, Rajashree Rana
Publikováno v:
Molecular Metabolism, Vol 29, Iss, Pp 99-113 (2019)
Molecular Metabolism
Molecular Metabolism
Objective Increases in hepatic and plasma cholesterol occur in patients with nonalcoholic fatty liver disease (NAFLD), although the reason for this is not well understood. We investigated whether Protease-Activated Receptor 2 (PAR2) plays a role in c
Autor:
Jun Zhang, Roger J. Davis, Meng Li, Christopher Q. Chen, Anna Mae Diehl, Mariam Aghajan, Ying Wang, Robert Win Maw Min, Tin Aung Than, Sanda Win, Neil Kaplowitz, Yibu Chen, Manal F. Abdelmalek, Filbert W.M. Aung, Ayako Suzuki
Publikováno v:
Journal of Clinical Investigation. 129:5278-5293
SH3 domain–binding protein that preferentially associates with Btk (SAB) is an outer-membrane docking protein for JNK-mediated impairment of mitochondrial function. Deletion of Sab in hepatocytes inhibits sustained JNK activation and cell death. Th
Autor:
De Lisa Fairweather, Sanda Win, Stefano Ballestri, Tin Aung Than, Amedeo Lonardo, Fabio Nascimbeni, Ayako Suzuki, Manal F. Abdelmalek
Publikováno v:
Hepatology
Despite tremendous research advancements in nonalcoholic fatty liver disease (NAFLD), our understanding of sex differences in NAFLD remains insufficient. This review summarizes the current knowledge on sex differences in NAFLD, identifies gaps, and d
Autor:
Cynthia D. Guy, Ying Wang, Anna Mae Diehl, Dana Portenier, Dawn Piercy, Matthew J Crowley, Andrea D. Coviello, Anastasia-Stefania Alexopoulos, Ranjan Sudan, Cynthia A. Moylan, Manal F. Abdelmalek, Keri A. Seymour, Ricardo Henao
Publikováno v:
Hepatology (Baltimore, Md.). 74(3)
BACKGROUND AND AIMS Whether glycemic control, as opposed to diabetes status, is associated with the severity of NAFLD is open for study. We aimed to evaluate whether degree of glycemic control in the years preceding liver biopsy predicts the histolog
Autor:
C. Stephen Djedjos, Raul Aguilar Schall, Zachary Goodman, B. Mccolgan, G. Mani Subramanian, Anna Mae Diehl, Nezam H. Afdhal, Andrew J. Muir, Jaime Bosch, Vlad Ratziu, Zobair M. Younossi, Manal F. Abdelmalek, Arun J. Sanyal, Stephen H. Caldwell, Mitchell L. Shiffman, Catherine Jia, John G. McHutchison, Stephen A. Harrison, Robert P. Myers
Publikováno v:
Hepatology
Progression of nonalcoholic steatohepatitis (NASH) is incompletely characterized. We analyzed data on longitudinal changes in liver histology, hepatic venous pressure gradient (HVPG), and serum markers of fibrosis in 475 patients with NASH with bridg
Autor:
Manal F. Abdelmalek, Margery A. Connelly, Stephen J. Rossi, Mary E. Rinella, Angelo H. Paredes, Stephen A. Harrison, Lei Ling, James F. Trotter, Mark J. Jaros, Alex M. DePaoli
Publikováno v:
Journal of Hepatology. 70:735-744
NGM282, an engineered analogue of the gut hormone FGF19, improves hepatic steatosis and fibrosis biomarkers in patients with non-alcoholic steatohepatitis (NASH). However, NGM282 increases serum cholesterol levels by inhibiting CYP7A1, which encodes
Autor:
B. Mccolgan, Eric Lawitz, Anna Mae Diehl, Catherine Jia, Manal F. Abdelmalek, Jaime Bosch, Zobair M. Younossi, G. Mani Subramanian, Mitchell L. Shiffman, John G. McHutchison, Reem Ghalib, Nezam H. Afdhal, Don C. Rockey, Andrew J. Muir, Raul Aguilar Schall, Vlad Ratziu, Zachary Goodman, Stephen H. Caldwell, Arun J. Sanyal, Stephen A. Harrison, Robert P. Myers
Publikováno v:
Gastroenterology. 155:1140-1153
Background & Aims Lysyl oxidase-like 2 contributes to fibrogenesis by catalyzing cross-linkage of collagen. We evaluated the safety and efficacy of simtuzumab, a monoclonal antibody against lysyl oxidase-like 2, in two phase 2b trials of patients wit